Literature DB >> 22543979

Postmortem distribution of tapentadol and N-desmethyltapentadol.

Scott J Larson1, Joseph Pestaner, Sunil K Prashar, Ciena Bayard, Lucas W Zarwell, Marie Pierre-Louis.   

Abstract

Postmortem distribution concentrations of the pain medication tapentadol and its metabolite N-desmethyltapentadol are reported. Tapentadol (Nucynta®) is a synthetic mu-opioid receptor agonist that also has norepinephrine reuptake inhibitor action. The laboratory received two cases. Case 1: a 19-year-old, morbidly obese male with sudden unexpected death. Toxicology results revealed tapentadol (femoral blood: 0.77 mg/L, liver: 1.65 mg/kg), N-desmethyltapentadol (femoral blood: 0.07 mg/L, liver: 0.19 mg/kg), diazepam (femoral blood: 0.04 mg/L), nordiazepam (femoral blood: 0.06 mg/L) and amiodarone (femoral blood: 5.30 mg/L). Case 2: a 60-year-old female who died from complications following hip replacement. Only tapentadol (femoral blood: 0.26 mg/L, liver: 0.52 mg/kg) was found in the toxicology results. Quantitative results of tapentadol/N-desmethyltapentadol were achieved using liquid chromatography-tandem mass spectrometry in multiple reactions monitoring mode. This is the first known distribution study of tapentadol and N-desmethyltapentadol values in postmortem cases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543979     DOI: 10.1093/jat/bks041

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  2 in total

1.  Evaluation of mitochondrial dysfunction due to oxidative stress in therapeutic, toxic and lethal concentrations of tramadol.

Authors:  Leila Mohammadnejad; Kambiz Soltaninejad; Mohammad Seyedabadi; Seyed Khosro Ghasem Pouri; Mohammad Shokrzadeh; Hamidreza Mohammadi
Journal:  Toxicol Res (Camb)       Date:  2021-11-08       Impact factor: 3.524

Review 2.  Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

Authors:  Ariane Stollenwerk; Melanie Sohns; Fabian Heisig; Christian Elling; Detlef von Zabern
Journal:  Adv Ther       Date:  2017-12-21       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.